CIMG Acquires Daren Business Technology Limited
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Source: PRnewswire
- Acquisition Agreement: CIMG's wholly-owned subsidiary DZR signed a share purchase agreement on February 5, 2026, to acquire 100% of Daren for approximately $40 million in shares, with closing expected within 30 days, marking a strategic expansion into the biopharmaceutical sector.
- Phased Payment Structure: The purchase consideration will be released in four phases—6%, 14%, 28%, and 52%—based on Daren's performance targets over a 3.5-year period, ensuring ongoing performance incentives for Daren and alignment with CIMG's growth objectives.
- Performance Targets Set: Daren must achieve increasing audited revenue targets from $29 million to $257 million between April 2026 and September 2029, which will enhance its competitiveness in the biopharmaceutical market while providing CIMG with a stable revenue stream.
- Strategic Diversification: CIMG's CEO Alice Wang stated that this acquisition is a key step in the company's diversification strategy, with plans to increase investments in the biopharmaceutical field, leveraging technological integration and innovative models to drive new growth engines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
